Seeking Alpha·3d ago
Neuronetics, Inc. (STIM) Q3 2026 Earnings Call TranscriptNeuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript
Neuronetics' quarterly revenue has rebounded from $16.4M in Q2 2024 to $41.6M in Q2 2026, but this recovery appears largely driven by a depressed base rather than proven sustained demand, and operating income has remained negative for ten consecutive quarters, with a Q2 2026 operating margin of -3.6%.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 4, 2026 | -$0.02+77.1% vs -$0.09 | $42M+3.8% vs $40M |
Q3 2026 Aug 11, 2026 | -$0.05+59.3% vs -$0.12 | $42M+3.5% vs $40M |
Q2 2026 May 5, 2026 | -$0.16+5.9% vs -$0.17 | $34M+0.8% vs $34M |
Q2 2026 Mar 17, 2026 | -$0.10+16.7% vs -$0.12 | $42M+2.7% vs $41M |
Neuronetics, Inc. (STIM) Q3 2026 Earnings Call Transcript
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar® TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to fourteen non-executive employees as described below.
Neuronetics NASDAQ: STIM reported third-quarter 2026 revenue growth, wider gross margin and a return to positive adjusted EBITDA, citing record NeuroStar system sales and continued revenue-cycle improvements across its Greenbrook clinic network.
Neuronetics (STIM) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.13 per share a year ago.
Benchmark STIM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Neuronetics, Inc. (STIM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $2.15 | $149.61M | -7.17 | 99.17% | -14.45% | -105.69% | — | |
| $27.17 | $224.97M | 20.89 | 15.28% | 15.32% | 23.38% | — | |
| $13.28 | $1.54B | -12.74 | 8.28% | -16.78% | -35.81% | — | |
| $10.17 | $1.72B | -13.23 | -38.24% | -7756.37% | -59.21% | — | |
| $89.99 | $4.94B | 26.34 | 10.74% | 13.01% | 15.35% | — | |
| $19.10 | $1.41B | 7.12 | 18.52% | 43.79% | 15.84% | — |
Neuronetics, Inc. (STIM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Neuronetics, Inc. (STIM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 17, 2026·SEC
Aug 11, 2026·SEC
Jul 20, 2026·SEC
Get notified when STIM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Neuronetics, Inc. (STIM) stock FAQ — growth, dividends, profitability & financials explained
Neuronetics, Inc. (STIM) reported $159.8M in revenue over the trailing twelve months. Revenue was $149.2M in fiscal year 2025. That is 336% more than the $34.2M of fiscal year 2016.
Neuronetics, Inc. (STIM) grew revenue by 23.0% over the trailing twelve months, compared with the twelve months before.
No. Neuronetics, Inc. (STIM) reported a net loss of $23.1M over the trailing twelve months.
Neuronetics, Inc. (STIM) had a return on equity (ROE) of -105.7% over the trailing twelve months. A negative ROE means the company lost money over the period.
Neuronetics, Inc. (STIM) had negative free cash flow of $8.4M over the trailing twelve months.
